{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:06:48Z","timestamp":1777586808647,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006108","name":"Kult\u00farna a Edukacn\u00e1 Grantov\u00e1 Agent\u00fara M\u0160VVa\u0160 SR","doi-asserted-by":"publisher","award":["024UPJ\\u0160-4\/2024"],"award-info":[{"award-number":["024UPJ\\u0160-4\/2024"]}],"id":[{"id":"10.13039\/501100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006109","name":"Scientific Grant Agency of the M\u0160VVa\u0160 and the SAV","doi-asserted-by":"publisher","award":["VEGA1\/0500\/23"],"award-info":[{"award-number":["VEGA1\/0500\/23"]}],"id":[{"id":"10.13039\/501100006109","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.yexcr.2026.114905","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T16:44:19Z","timestamp":1769186659000},"page":"114905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Overexpression of biliverdin reductase A leads to ROS-independent sensitization of ovarian adenocarcinoma cells to gemcitabine"],"prefix":"10.1016","volume":"456","author":[{"given":"Zuzana","family":"Sol\u00e1rov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krist\u00edna","family":"Dankov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9900-9995","authenticated-orcid":false,"given":"Pavol","family":"Harvanik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Bober","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Majerov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9987-1556","authenticated-orcid":false,"given":"Radka","family":"Michalkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mangesh","family":"Bhide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1287-2979","authenticated-orcid":false,"given":"Peter","family":"Sol\u00e1r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexcr.2026.114905_bib1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fphar.2015.00119","article-title":"Biliverdin reductase: a target for cancer therapy?","volume":"6","author":"Gibbs","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.yexcr.2026.114905_bib2","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2147\/CMAR.S242531","article-title":"Biliverdin reductase A (BLVRA) promotes colorectal cancer cell progression by activating the Wnt\/beta-catenin signaling pathway","volume":"12","author":"Mao","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.yexcr.2026.114905_bib3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10735-023-10179-w","article-title":"BLVRA exerts its biological effects to induce malignant properties of hepatocellular carcinoma cells via Wnt\/beta-catenin pathway","volume":"55","author":"Chen","year":"2024","journal-title":"J. Mol. Histol."},{"key":"10.1016\/j.yexcr.2026.114905_bib4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s12943-025-02375-x","article-title":"Oxidative stress in cancer: from tumor and microenvironment remodeling to therapeutic frontiers","volume":"24","author":"Liang","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.yexcr.2026.114905_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abh3066","article-title":"Biliverdin reductase bridges focal adhesion kinase to Src to modulate synaptic signaling","volume":"15","author":"Vasavda","year":"2022","journal-title":"Sci. Signal."},{"key":"10.1016\/j.yexcr.2026.114905_bib6","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1096\/fj.201600330RR","article-title":"Interaction of human biliverdin reductase with Akt\/protein kinase B and phosphatidylinositol-dependent kinase 1 regulates glycogen synthase kinase 3 activity: a novel mechanism of Akt activation","volume":"30","author":"Miralem","year":"2016","journal-title":"FASEB J."},{"key":"10.1016\/j.yexcr.2026.114905_bib7","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.tem.2015.02.001","article-title":"Biliverdin reductase isozymes in metabolism","volume":"26","author":"O'Brien","year":"2015","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.yexcr.2026.114905_bib8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.canlet.2010.09.003","article-title":"Overexpression of biliverdin reductase enhances resistance to chemotherapeutics","volume":"300","author":"Florczyk","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.yexcr.2026.114905_bib9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1042\/CS20242825","article-title":"Heme oxygenase, biliverdin reductase, and bilirubin pathways regulate oxidative stress and insulin resistance: a focus on diabetes and therapeutics","volume":"139","author":"Lee","year":"2025","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.yexcr.2026.114905_bib10","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5628946","article-title":"Biliverdin reductase A protects lens epithelial cells against oxidative damage and cellular senescence in age-related cataract","volume":"2022","author":"Huang","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.yexcr.2026.114905_bib11","first-page":"3","article-title":"Gemcitabine: metabolism, mechanisms of action, and self-potentiation","volume":"22","author":"Plunkett","year":"1995","journal-title":"Semin. Oncol."},{"issue":"Suppl 5","key":"10.1016\/j.yexcr.2026.114905_bib12","doi-asserted-by":"crossref","first-page":"v7","DOI":"10.1093\/annonc\/mdj941","article-title":"Cellular pharmacology of gemcitabine","volume":"17","author":"Mini","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.yexcr.2026.114905_bib13","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0026-895X(25)09518-5","article-title":"Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine","volume":"38","author":"Heinemann","year":"1990","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.yexcr.2026.114905_bib14","first-page":"16","article-title":"Preclinical combination therapy with gemcitabine and mechanisms of resistance","volume":"23","author":"Peters","year":"1996","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.yexcr.2026.114905_bib15","first-page":"4417","article-title":"Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine)","volume":"50","author":"Hertel","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexcr.2026.114905_bib16","first-page":"19","article-title":"Induction of apoptosis by gemcitabine","volume":"22","author":"Huang","year":"1995","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.yexcr.2026.114905_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2025.1702720","article-title":"Clinical application and drug resistance mechanism of gemcitabine","volume":"13","author":"Zhang","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.yexcr.2026.114905_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.307","article-title":"Gemcitabine-mediated tumour regression and p53-dependent gene expression: implications for colon and pancreatic cancer therapy","volume":"4","author":"Hill","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.yexcr.2026.114905_bib19","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1158\/1535-7163.MCT-06-0633","article-title":"H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation","volume":"6","author":"Ewald","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.yexcr.2026.114905_bib20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s002800051004","article-title":"The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization","volume":"45","author":"Chen","year":"2000","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.yexcr.2026.114905_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/bies.202200122","article-title":"Transcription-independent functions of p53 in DNA repair pathway selection","volume":"45","author":"Wang","year":"2023","journal-title":"Bioessays"},{"key":"10.1016\/j.yexcr.2026.114905_bib22","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/cdd.2011.96","article-title":"Molecular definitions of cell death subroutines: recommendations of the nomenclature committee on cell death 2012","volume":"19","author":"Galluzzi","year":"2012","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.yexcr.2026.114905_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081162","article-title":"Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions","volume":"8","author":"Marullo","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.yexcr.2026.114905_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108642","article-title":"Cisplatin in the era of PARP inhibitors and immunotherapy","volume":"258","author":"Duan","year":"2024","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.yexcr.2026.114905_bib25","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","article-title":"Doxorubicin pathways: pharmacodynamics and adverse effects","volume":"21","author":"Thorn","year":"2011","journal-title":"Pharmacogenet. Genom."},{"key":"10.1016\/j.yexcr.2026.114905_bib26","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.yjmcc.2012.03.006","article-title":"Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies","volume":"52","author":"Octavia","year":"2012","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.yexcr.2026.114905_bib27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fphar.2012.00045","article-title":"Physiological antioxidative network of the bilirubin system in aging and age-related diseases","volume":"3","author":"Kim","year":"2012","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.yexcr.2026.114905_bib28","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.bbrc.2013.09.120","article-title":"Biliverdin reductase plays a crucial role in hypoxia-induced chemoresistance in human glioblastoma","volume":"440","author":"Kim","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.yexcr.2026.114905_bib29","first-page":"822","article-title":"Ammine\/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines","volume":"52","author":"Kelland","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexcr.2026.114905_bib30","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"Galluzzi","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.yexcr.2026.114905_bib31","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/annonc\/mdm283","article-title":"Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR\/GISCAD intergroup study and a German multicenter study","volume":"18","author":"Heinemann","year":"2007","journal-title":"Ann. Oncol."}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482726000212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482726000212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T20:08:45Z","timestamp":1777406925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482726000212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0014482726000212"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2026.114905","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overexpression of biliverdin reductase A leads to ROS-independent sensitization of ovarian adenocarcinoma cells to gemcitabine","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2026.114905","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114905"}}